Shire and Parion Sciences ally on development of ophthalmic drug

Shire has announced a new drug development partnership with Parion Sciences that focuses on a new therapy for ophthalmic indications.

The deal will see Shire gain exclusive worldwide rights to develop and commercialise P-321, an investigational epithelial sodium channel inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.

Presently in phase II development, the compound addresses tear volume deficiency and promotes ocular surface healing by inhibiting ENaC, a channel that is thought to block the absorption of tears.

Current prescription treatments target the effects of ocular inflammation, but this new treatment would offer an opportunity to tackle the causes of the condition more directly.

Dr Flemming Ornskov, chief executive officer of Shire, said: "This is an opportunity to apply our knowledge and experience from ophthalmics and dry eye disease for further innovation in this space. If approved, P-321 would expand our eye care portfolio."

Ageing and gender are known as traditional risk factors of chronic dry eye disease, while emerging risk factors include prolonged screen usage, contact lens use and cataract or refractive surgery.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.